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Influenza (Flu)
Weekly U.S. Influenza Surveillance Report
Key Updates for Week 5, ending February 1, 2020
Key indicators that track flu activity remain high and, after falling during the first two weeks of the year,
increased over the last three weeks. Indicators that track overall severity (hospitalizations and deaths)
are not high at this point in the season.
Viruses
Clinical Labs
The percentage of respiratory specimens testing positive for influenza at clinical laboratories increased from 28.4%
last week to 29.8% this week.
Public Health Labs
Numbers of influenza B/Victoria and A(H1N1)pdm09 viruses are approximately equal for the season overall, with
continued increases in influenza A(H1N1)pdm09 viruses in recent weeks.
Virus Characterization
Genetic and antigenic characterization and antiviral susceptibility of influenza viruses collected in the U.S. are
summarized in this report.
Illness
Outpatient Illness: ILINet
Visits to health care providers for influenza-like illness (ILI) increased from 6.0% last week to 6.7% this week. All
regions remain above their baselines.
Outpatient Illness: ILINet Activity Map
The number of jurisdictions experiencing high ILI activity increased from 44 last week to 47 this week.
Geographic Spread
The number of jurisdictions reporting regional or widespread influenza activity remained at 51 this week.
Severe Disease
Hospitalizations
The overall hospitalization rate for the season increased to 35.5 per 100,000. This is similar to what has been seen at
this time during recent seasons.
P&I Mortality
The percentage of deaths attributed to pneumonia and influenza is 7.1%, below the epidemic threshold of 7.2%.
Pediatric Deaths
10 influenza-associated pediatric deaths occurring during the 2019-2020 season were reported this week. The total
for the season is 78.
All data are preliminary and may change as more reports are received.
A description of the CDC influenza surveillance system, including methodology and detailed descriptions of each data
component is available on the surveillance methods page.
Additional information on the current and previous influenza seasons for each surveillance component are available on
FluView Interactive.
U.S. Virologic Surveillance
Clinical Laboratories
Key Points
Outpatient ILI and laboratory data remain elevated and increased again this week. Nationally, and in some
regions, the proportion of influenza A(H1N1)pdm09 viruses compared to influenza B viruses is increasing.
Overall, hospitalization rates remain similar to this time during recent seasons, but rates among children and
young adults are higher at this time than in recent seasons.
Pneumonia and influenza mortality has been low, but 78 influenza-associated deaths in children have been
reported so far this season.
CDC estimates that so far this season there have been at least 22 million flu illnesses, 210,000 hospitalizations
and 12,000 deaths from flu.
Flu vaccine effectiveness estimates will be available later this month, but vaccination is always the best way to
prevent flu and its potentially serious complications.
Antiviral medications are an important adjunct to flu vaccine in the control of influenza. Almost all (>99%) of the
influenza viruses tested this season are susceptible to the four FDA-approved influenza antiviral medications
recommended for use in the U.S. this season.
The results of tests performed by clinical laboratories nationwide are summarized below. Data from clinical laboratories
(the percentage of specimens tested that are positive for influenza) are used to monitor whether influenza activity is
increasing or decreasing.
Week 5
Data Cumulative since 
September 29, 2019
(week 40)
No. of specimens tested 53,247 738,331
No. of positive specimens (%) 15,875 (29.8%) 129,997 (17.6%)
Positive specimens by type   
    Influenza A 8,637 (54.4%) 52,928 (40.7%)
    Influenza B 7,238 (45.6%) 77,069 (59.3%)
The predominant virus also varies by age group. Nationally, for the season overall, influenza B viruses are the most
commonly reported influenza viruses among children and young adults age 0-4 years (56% of reported viruses) and 5-24
years (73% of reported viruses), while A(H1N1)pdm09 viruses are the most commonly reported influenza viruses among
persons 25-64 years (53% of reported viruses) and 65 years of age and older (60% of reported viruses). For this season,
52% of influenza positive specimens reported by public health laboratories were among persons less than 25 years of age
and less than 13% were from persons age 65 and older.
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Public Health Laboratories
The results of tests performed by public health laboratories nationwide are summarized below. Data from public health
laboratories are used to monitor the proportion of circulating viruses that belong to each influenza subtype/lineage.
Week 5
Data Cumulative since
September 29, 2019 
(week 40)
No. of specimens tested 2,129 46,258
No. of positive specimens 1,365 24,403
Positive specimens by type/subtype   
         Influenza A 898 (65.8%) 11,670 (47.8%)
            (H1N1)pdm09 810 (95.7%) 10,087 (88.9%)
             H3N2 36 (4.3%) 1,255 (11.1%)
             Subtyping not performed 52 328
        Influenza B 467 (34.2%) 12,733 (52.2%)
            Yamagata lineage 2 (0.5%) 168 (1.7%)
            Victoria lineage 393 (99.5%) 9,765 (98.3%)
            Lineage not performed 72 2,800
Nationally, influenza B/Victoria viruses have been reported more frequently than other influenza viruses this season.
However, during recent weeks, influenza A(H1N1)pdm09 viruses have been reported more frequently than B/Victoria
viruses. The predominant virus varies by region. Regional and state level data about circulating influenza viruses can be
found on FluView Interactive.
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Additional virologic surveillance information for current and past seasons: 
Surveillance Methods | FluView Interactive: National, Regional, and State Data or Age Data
Influenza Virus Characterization
CDC performs genetic and antigenic characterization of U.S. viruses submitted from state and local health laboratories
using Right Size Roadmap submission guidance. These data are used to compare how similar the currently circulating
influenza viruses are to the reference viruses used for developing new influenza vaccines and to monitor evolutionary
changes that continually occur in circulating influenza. Antigenic characterization data are based on an animal model
(influenza-naive ferrets), and do not reflect pre-existing protection provided by past influenza infections and vaccinations.
Additional antigenic characterization studies involving people vaccinated with current influenza vaccines are conducted
later in the season; these data account for pre-existing protection in different populations against circulating influenza
viruses. Genetic and antigenic characterization data are not used to make calculations about vaccine effectiveness (VE)
CDC conducts VE studies each year to measure the benefits of flu vaccines in people.
CDC genetically characterized 1,260 influenza viruses collected in the U.S. from September 29, 2019, to February 1,
2020.
Virus
Subtype or
Lineage
Genetic Characterization
Total No. of
Subtype/Lineage
Tested
        
Clade
Number (% of
subtype/lineage
tested)
        
Subclade
Number (% of
subtype/lineage
tested)
A/H1 397
6B.1A 397 (100%)
A/H3 301
3C.2a 290 (96.3%) 2a1 290 (96.3%)
  2a2 0
   2a3 0
2a4 0
3C.3a 11 (3.7%) 3a 11 (3.7%)
B/Victoria 509
V1A 509 (100%) V1A 0
V1A.1 42 (8.3%)
V1A.3 467 (91.7%)
B/Yamagata 53
Y3 53 (100%)
CDC antigenically characterizes a subset of influenza viruses by hemagglutination inhibition (HI) or neutralization
based Focus Reduction assays (FRA). Antigenic drift is evaluated by comparing antigenic properties of cell-propagated
reference viruses representing currently recommended vaccine components with those of cell-propagated circulating
viruses. CDC antigenically characterized 241 influenza viruses collected in the United States from September 29, 2019, to
February 1, 2020. These data are not used to make calculations about vaccine effectiveness (VE). CDC conducts VE studies
each year to measure the benefits of flu vaccines in people.
Influenza A Viruses
A (H1N1)pdm09: 74 A(H1N1)pdm09 viruses were antigenically characterized by HI with ferret antisera, and all 74
(100%) were antigenically similar (reacting at titers that were within 4-fold of the homologous virus titer) to cell-
propagated A/Brisbane/02/2018-like reference viruses representing the A(H1N1)pdm09 component for the 2019-20
Northern Hemisphere influenza vaccines.
A (H3N2): 69 A(H3N2) viruses were antigenically characterized by FRA with ferret antisera, and 30 (43.5%) were
antigenically similar to cell-propagated A/Kansas/14/2017-like reference viruses representing the A(H3N2)
component for the 2019-20 Northern Hemisphere influenza vaccines.
Influenza B Viruses
B/Victoria: 88 B/Victoria lineage viruses, including viruses from both co-circulating sub-clades, were antigenically
characterized by HI with ferret antisera, and 53 (60.2%) were antigenically similar to cell-propagated
B/Colorado/06/2017-like reference viruses representing the B/Victoria component for the 2019-20 Northern
Hemisphere influenza vaccines.
B/Yamagata: 10 B/Yamagata lineage viruses were antigenically characterized by HI with ferret antisera, and all 10
(100%) were antigenically similar to cell-propagated B/Phuket/3073/2013-like reference viruses representing the
B/Yamagata component for the 2019-20 Northern Hemisphere influenza vaccines.
CDC assesses susceptibility of influenza viruses to the antiviral medications including the neuraminidase
inhibitors (oseltamivir, zanamivir, and peramivir) and the PA endonuclease inhibitor baloxavir using next generation
sequence analysis supplemented by laboratory assays. Viruses collected in the United States since September 29, 2019,
were tested for antiviral susceptibility as follows:
Antiviral Medication
Total
Viruses
A/H1 A/H3 B/Victoria B/Yamagata
Neuraminidase
Inhibitors
Oseltamivir
Viruses Tested 1,192 374 287 481 50
Reduced
Inhibition
(0.0%) (0.0%) (0.0%) (0.0%) (0.0%)
Highly
Reduced
Inhibition
1 (0.1%)
1
(0.3%)
(0.0%) (0.0%) (0.0%)
Peramivir
Viruses Tested 1,192 374 287 481 50
Reduced
Inhibition
(0.0%) (0.0%) (0.0%) (0.0%) (0.0%)
Highly
Reduced
Inhibition
1 (0.1%)
1
(0.3%)
(0.0%) (0.0%) (0.0%)
Zanamivir
Viruses Tested 1,192 374 287 481 50
Reduced
Inhibition
1 (0.1%) (0.0%) (0.0%) 1 (0.2%) (0.0%)
Highly
Reduced
Inhibition
(0.0%) (0.0%) (0.0%) (0.0%) (0.0%)
PA Endonuclease
Inhibitor
Baloxavir
Viruses Tested 1,246 395 294 504 53
Reduced
Susceptibility
(0.0%) (0.0%) (0.0%) (0.0%) (0.0%)
A total of 259 additional viruses (118 H1pdm09, 19 H3, and 122 B) collected in Alabama, Alaska, Florida, Illinois, Iowa,
Michigan, Nevada, New York, North Carolina, Pennsylvania, Virginia, and Wisconsin were analyzed for resistance to
neuraminidase inhibitors by pyrosequencing assay. Two (1.7%) of the 118 A(H1N1)pdm09 viruses tested had the H275Y
amino acid substitution in the neuraminidase that confers resistance to oseltamivir and potential resistance to peramivir.
No markers of resistance to neuraminidase inhibitors were detected in A(H3N2) and type B viruses tested.
Outpatient Illness Surveillance
ILINet
Nationwide during week 5, 6.7% of patient visits reported through the U.S. Outpatient Influenza-like Illness Surveillance
Network (ILINet) were due to influenza-like illness (ILI). This percentage is above the national baseline of 2.4%.
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On a regional level, the percentage of outpatient visits for ILI ranged from 4.0% to 10.9% during week 5. All regions
reported a percentage of outpatient visits for ILI above their region-specific baselines.
ILI Activity Map
Data collected in ILINet are used to produce a measure of ILI activity* by state.
During week 5, the following ILI activity levels were experienced:
High – New York City, Puerto Rico, and 45 states (Alabama, Arizona, Arkansas, California, Colorado, Connecticut,
Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts,
Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, New Jersey, New Mexico, New York, North Carolina,
North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee,
Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming)
Moderate – the District of Columbia, the U.S. Virgin Islands, and two states (Nevada and New Hampshire)
Low - two states (Alaska and Delaware)
Minimal - one state (Idaho)
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Influenza-Like Illness (ILI) Activity Level Indicator Determined by Data Reported to ILINet
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*Data collected in ILINet may disproportionally represent certain populations within a state, and therefore, may not accurately depict the full picture of
influenza activity for the whole state. Differences in the data presented here by CDC and independently by some state health departments likely represent
differing levels of data completeness with data presented by the state likely being the more complete.
Additional information about medically attended visits for ILI for current and past seasons: 
Surveillance Methods | FluView Interactive: National, Regional, and State Data or ILI Activity Map
Geographic Spread of Influenza as Assessed by State and
Territorial Epidemiologists
The influenza activity reported by state and territorial epidemiologists indicates geographic spread of influenza viruses
but does not measure the severity of influenza activity.
During week 5, the following influenza activity was reported:
Widespread – Puerto Rico and 48 states (Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut,
Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland,
Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New
Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, Rhode Island, South
Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and
Wyoming)
Regional – two states (Hawaii and Oregon)
Local – the District of Columbia
Sporadic – the U.S. Virgin Islands
Guam did not report.
A Weekly Influenza Surveillance Report Prepared by the Influenza Division
Weekly Influenza Activity Estimates Reported by State and Territorial Epidemiologists*
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Additional geographic spread surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive
Influenza-Associated Hospitalizations
The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-
confirmed influenza-related hospitalizations in select counties in the Emerging Infections Program (EIP) states and
Influenza Hospitalization Surveillance Project (IHSP) states.
A total of 10,314 laboratory-confirmed influenza-associated hospitalizations were reported by FluSurv-NET sites between
October 1, 2019 and February 1, 2020; 6,416 (62.2%) were associated with influenza A virus, 3,835 (37.2%) with influenza B
virus, 31 (0.3%) with influenza A virus and influenza B virus co-infection, and 32 (0.3%) with influenza virus for which the
type was not determined. Among those with influenza A subtype information, 1,397 (92.6%) were A(H1N1)pdm09 virus
and 112 (7.4%) were A(H3N2).
The overall cumulative hospitalization rate was 35.5 per 100,000 population which is similar to what has been seen
during recent previous influenza seasons at this time of year. Rates in children and young adults are higher than at this
time in recent seasons.
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The highest rate of hospitalization is among adults aged ≥65, followed by children aged 0-4 years and adults aged 50-64
years.
Age Group
2019-2020 Season
Cumulative Rate per 100,000 Population
Overall 35.5
0-4 years 56.9
5-17 years 15.1
18-49 years 20.2
50-64 years 44.9
65+ years 85.1
Among 1,332 hospitalized adults with information on underlying medical conditions, 91.6% had at least one reported
underlying medical condition, the most commonly reported were cardiovascular disease, metabolic disorder, obesity, and
chronic lung disease. Among 297 hospitalized children with information on underlying medical conditions, 46.5% had at
least one underlying medical condition; the most commonly reported was asthma. Among 253 hospitalized women of
childbearing age (15-44 years) with information on pregnancy status, 25.3% were pregnant.
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Additional hospitalization surveillance information for current and past seasons and additional age groups:
Surveillance Methods | FluView Interactive: Rates by Age or Patient Characteristics
Pneumonia and Influenza (P&I) Mortality Surveillance
Based on National Center for Health Statistics (NCHS) mortality surveillance data available on February 6, 2020, 7.1% of
the deaths occurring during the week ending January 25, 2020 (week 4) were due to P&I. This percentage is below the
epidemic threshold of 7.2% for week 4.
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Additional pneumonia and influenza mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive
Influenza-Associated Pediatric Mortality
Ten influenza-associated pediatric deaths occurring during the 2019-2020 season between weeks 1 and 4 (the weeks
ending January 4, 2020 and January 25, 2020) were reported to CDC during week 5. Seven were associated with influenza
B viruses; none had a lineage determined. Three were associated with influenza A viruses, and one was subtyped and
was an A(H1N1)pdm09 virus.
One influenza-associated pediatric death occurring during the 2018-2019 season in week 30 (the week ending July 27,
2019) was reported to CDC during week 5, bringing the total during that season to 144. This was associated with an
influenza A virus.
Of the 78 influenza-associated pediatric deaths occurring during the 2019-2020 season and reported to CDC:
52 deaths were associated with influenza B viruses, and nine had a lineage determined; all were B/Victoria viruses.
26 deaths were associated with influenza A viruses, and 16 were subtyped; all were A(H1N1)pdm09 viruses.
View Full Screen
Additional pediatric mortality surveillance information for current and past seasons:
Surveillance Methods | FluView Interactive
Additional National and International Influenza Surveillance
Information
FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of
the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create
customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups
and a variety of other demographics. To access these tools, visit http://www.cdc.gov/flu/weekly/fluviewinteractive.htm
National Institute for Occupational Safety and Health: Monthly surveillance data on the prevalence of health-
related workplace absenteeism among full-time workers in the United States are available from NIOSH at
https://www.cdc.gov/niosh/topics/absences/default.html
U.S. State and local influenza surveillance:Select a jurisdiction below to access the latest local influenza information
Alabama Alaska Arizona Arkansas California
Colorado Connecticut Delaware
District of
Columbia
Florida
Georgia Hawaii Idaho Illinois Indiana
Iowa Kansas Kentucky Louisiana Maine
Maryland Massachusetts Michigan Minnesota Mississippi
Missouri Montana Nebraska Nevada New Hampshire
New Jersey New Mexico New York North Carolina North Dakota
Ohio Oklahoma Oregon Pennsylvania Rhode Island
South Carolina South Dakota Tennessee Texas Utah
Vermont Virginia Washington West Virginia Wisconsin
Wyoming New York City Puerto Rico Virgin Islands
World Health Organization: Additional influenza surveillance information from participating WHO member nations is
available through FluNet and the Global Epidemiology Reports.
WHO Collaborating Centers for Influenza located in Australia, China, Japan, the United Kingdom, and the United
States (CDC in Atlanta, Georgia).
Europe: For the most recent influenza surveillance information from Europe, please see WHO/Europe and the European
Centre for Disease Prevention and Control at http://www.flunewseurope.org/.
Public Health Agency of Canada: The most up-to-date influenza information from Canada is available at
http://www.phac-aspc.gc.ca/fluwatch/
Public Health England: The most up-to-date influenza information from the United Kingdom is available at
https://www.gov.uk/government/statistics/weekly-national-flu-reports
Any links provided to non-Federal organizations are provided solely as a service to our users. These links do
not constitute an endorsement of these organizations or their programs by CDC or the Federal Government,
and none should be inferred. CDC is not responsible for the content of the individual organization web
pages found at these links.
An overview of the CDC influenza surveillance system, including methodology and detailed descriptions of each data
component, is available at: http://www.cdc.gov/flu/weekly/overview.htm.
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